Private Equity, DSOs & The Exit Game: What Nobody Tells You Until It’s Too Late

High curiosity, high stakes, and almost no straight talk. Here’s what buyers actually look for — and why some deals collapse on the finish line.

Hamza Asumah, MD, MBA, MPH

I’ve been in rooms where the letter of intent is on the table. The number looks life-changing. The founder is nodding, smiling, already spending the proceeds in their head.

And they don’t fully understand what they’re agreeing to.

That’s not a horror story. It’s Tuesday in healthcare M&A.

Today, I want to pull back the curtain on private equity in healthcare — what it is, what buyers actually want, why some deals fall apart on the finish line, and what you should be building toward right now if an exit is anywhere on your horizon.

Why Private Equity Is in Healthcare — and Why It’s Not Going Anywhere

Private equity firms invest in healthcare for a convergence of reasons that, from their perspective, make it close to ideal.

Healthcare cash flows are strong and relatively recession-resistant. Demand doesn’t evaporate in a downturn the way discretionary spending does — people still need clinical care. The sector has significant regulatory and credentialing barriers to entry, which protect incumbents from easy competition. And perhaps most importantly for PE strategy — healthcare is deeply fragmented.

Fragmented markets with strong unit economics are PE’s favorite hunting ground. The roll-up thesis is straightforward: acquire a platform group, bolt on smaller operators, standardize and improve operations across the portfolio, and sell the combined entity at a significantly higher valuation than the sum of the individual parts.

THE MULTIPLE EXPANSION MATH Acquire: 5-location group at 6x EBITDA Add: 10 more locations, improve margins, grow revenue Sell: 15-location group at 12–14x EBITDA   Even with identical EBITDA per location, multiple expansion alone can double the equity value of the original investment.   That’s not magic. That’s the arbitrage of scale and financial engineering.

Understanding this isn’t cynicism — it’s clarity. PE firms are not in healthcare out of altruism, and they don’t pretend to be. Understanding their actual motivation helps you position your business to align with what they genuinely value.

The 5 Questions Every Buyer Asks Before Writing a Check

When a PE firm or a large DSO evaluates a healthcare acquisition, there’s a structured logic to their diligence. Let me give you the five questions that drive every serious deal conversation.

1. Is the EBITDA real?

This is the question that kills more deals than any other — not because sellers are dishonest, but because healthcare EBITDA is genuinely complex to normalize. Owner compensation often includes personal expenses. Related-party transactions distort the books. Revenue recognition timing creates apparent performance that doesn’t survive scrutiny.

Sophisticated buyers spend weeks adjusting and normalizing your financials. If what they find doesn’t match what was presented in the teaser, the deal doesn’t just get repriced — trust breaks. And in M&A, trust, once broken, is rarely recovered.

2. Is there key-person dependency?

If you — the founder, the clinical leader, the rainmaker — are the reason this business works, every sophisticated buyer sees that as risk they have to price. What happens to revenue when you step back? If the honest answer is ‘it drops significantly,’ you are either going to accept a lower multiple, a longer earnout period, or both. The solution is building your management bench before you go to market — not after you receive your first offer.

3. Is there a credible growth story?

PE is not buying your history. They’re buying your future cash flows. Where does the next 30% of revenue come from? Is there an underserved market segment, a service line you haven’t launched, a geography that’s adjacent and accessible? If you can’t articulate a specific, credible growth thesis — not generic optimism but a concrete plan with market support — buyers will assume the business has plateaued. Plateaued businesses don’t command premium multiples.

4. Are the systems transferable?

This is the operational version of key-person dependency. Can someone who isn’t you run this business — not just survive it, but actually run it well? Are your processes documented? Is your technology infrastructure modern and auditable? Are your HR records, billing systems, and patient data organized in a way that survives the scrutiny of a diligence team?

Nothing slows down — or kills — a healthcare deal faster than discovering during diligence that the business effectively runs on the founder’s memory and a collection of spreadsheets scattered across personal Dropbox folders.

5. What does the compliance picture look like?

Especially in DSO and specialty group transactions, sophisticated buyers are increasingly rigorous about compliance. Active regulatory investigations, patterns of billing anomalies, unresolved HR issues, credentialing gaps — these are not negotiating points. They are deal-stoppers. Clean compliance records and a demonstrable, documented commitment to clinical quality are prerequisites for a premium transaction.

Why Deals Fall Apart (The Lessons Nobody Advertises)

Let me tell you about the deals that don’t close — because the pattern is instructive.

Financial Surprises in Diligence

The buyer’s accountants find something. It might be a payroll tax liability nobody knew about. It might be receivables carried at face value long past their realistic collection date. It might be a related-party lease that was never properly disclosed. These surprises don’t just change the economics — they destroy the relationship. And M&A transactions are fundamentally trust transactions. Once trust breaks, repricing is the optimistic outcome. Collapse is the more common one.

Leadership Instability During the Process

Deal processes take six to twelve months from initial LOI to close. During that time, word leaks — sometimes deliberately, sometimes accidentally. Key staff get nervous. Practice managers start interviewing elsewhere. Top producers begin to wonder whether they have a future in the new organization. When a buyer discovers mid-diligence that two location managers and a top-producing provider exited in the last 90 days, the risk calculus changes dramatically and immediately.

Misaligned Post-Close Expectations

This is the most underestimated failure mode. Sellers imagine more resources, more support, more operational freedom. Buyers imagine rapid implementation of their playbook, access to your patient data, and your enthusiastic cooperation with integration. When these expectations collide — and they almost always do, within the first six months — what started as a success story becomes a quiet cautionary tale.

The exit isn’t the end of the story. For most founders in a roll-up structure, it’s the beginning of a two-to-three-year chapter where they still have to perform. Read every clause of what you’re signing before you sign it.

Your 24-Month Exit Roadmap

If you’re building toward a transaction — even if it’s years away — here is the roadmap I’d give you in broad strokes.

In months one through six: clean up your financials. Get to reviewed or audited statements. Document your EBITDA with clean add-backs. Understand, with precision, what your business is worth at current performance — not what you hope it’s worth.

In months seven through twelve: build your management bench. Your exit valuation increases meaningfully when the business demonstrably runs without you. That means a strong operations lead, a reliable clinical director, and a finance function that can close the books without your involvement.

In months thirteen through eighteen: accelerate. PE pays more for businesses on an upward trajectory. EBITDA growth in the twelve months before a transaction is valued not just in trailing numbers but in the buyer’s projection model. A business growing at 25% annually commands a different conversation than one that has been flat for two years.

In months nineteen through twenty-four: run a competitive process. The worst thing you can do is accept the first offer from the first interested buyer. Go to market with an experienced healthcare M&A advisor, create real competition among multiple parties, and let the market set your price. The difference between a negotiated bilateral process and a properly structured competitive process can be one to three full turns of EBITDA — on a transaction in the tens of millions, that’s life-changing money.

Start Now, Not When You’re Ready to Sell

The healthcare businesses that capture premium exit valuations didn’t start thinking about it six months before going to market. They started building toward it three to five years out — often before they were sure they even wanted to sell.

Because the truth is: building a business that would command a premium exit multiple is identical to building a business that is genuinely excellent. The two goals are the same goal. Clean financials. Strong systems. Deep leadership bench. Consistent growth.

Whether you exit or not, that’s the right business to build.